Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT: Difference between revisions
Aysha Aslam (talk | contribs) |
Aysha Aslam (talk | contribs) |
||
Line 10: | Line 10: | ||
|colspan="1" style="text-align:center; background:LightGreen"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |colspan="1" style="text-align:center; background:LightGreen"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Vagal maneuvers are recommended for acute treatment in patients with orthodromic AVRT <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Vagal maneuvers are recommended for acute treatment in patients with orthodromic AVRT <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Adenosine is beneficial for acute treatment in patients with orthodromic AVRT <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Adenosine is beneficial for acute treatment in patients with orthodromic AVRT <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with | ||
AVRT if vagal maneuvers or adenosine are ineffective or not feasible <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | AVRT if vagal maneuvers or adenosine are ineffective or not feasible <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.'''Synchronized cardioversion is recommended for acute treatment in hemodynamically stable patients with AVRT | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' Synchronized cardioversion is recommended for acute treatment in hemodynamically stable patients with AVRT | ||
when pharmacological therapy is ineffective or contraindicated <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | when pharmacological therapy is ineffective or contraindicated <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''5.'''Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''5.''' Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with | ||
pre-excited AF<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR ]])'' <nowiki>"</nowiki> | pre-excited AF<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR ]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''6.'''Ibutilide or intravenous procainamide is beneficial for acute treatment in patients with pre-excited AF | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''6.''' Ibutilide or intravenous procainamide is beneficial for acute treatment in patients with pre-excited AF | ||
who are hemodynamically stable <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | who are hemodynamically stable <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | ||
Line 37: | Line 37: | ||
|colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Intravenous diltiazem, verapamil <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' or beta blockers can be effective for acute treatment in patients with orthodromic AVRT who do not have preexcitation | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Intravenous diltiazem, verapamil <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' or beta blockers can be effective for acute treatment in patients with orthodromic AVRT who do not have preexcitation | ||
on their resting ECG during sinus rhythm <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | on their resting ECG during sinus rhythm <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Line 45: | Line 45: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Intravenous beta blockers, diltiazem, or verapamil might be considered for acute treatment in patients with orthodromic | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Intravenous beta blockers, diltiazem, or verapamil might be considered for acute treatment in patients with orthodromic | ||
AVRT who have pre-excitation on their resting ECG and have not responded to other therapies<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B-R]])'' <nowiki>"</nowiki> | AVRT who have pre-excitation on their resting ECG and have not responded to other therapies<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B-R]])'' <nowiki>"</nowiki> | ||
Line 54: | Line 54: | ||
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]](harm) | |colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]](harm) | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.'''Intravenous digoxin, intravenous amiodarone, intravenous or oral beta blockers, diltiazem, and verapamil are | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Intravenous digoxin, intravenous amiodarone, intravenous or oral beta blockers, diltiazem, and verapamil are | ||
potentially harmful for acute treatment in patients with pre-excited AF ( <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | potentially harmful for acute treatment in patients with pre-excited AF ( <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | ||
|- | |- |
Revision as of 16:03, 27 October 2016
Supraventricular tachycardia Microchapters |
Differentiating Among the Different Types of Supraventricular Tachycardia |
---|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
Diagnosis |
Treatment |
2015 ACC/AHA Guideline Recommendations |
Case Studies |
Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT On the Web |
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
FDA on Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
CDC on Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT in the news |
Blogs on Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Management of Orthodromic AVRT
Acute Treatment of Orthodromic AVRT
Class I |
"1. Vagal maneuvers are recommended for acute treatment in patients with orthodromic AVRT "(Level of Evidence: B-R) " |
"2. Adenosine is beneficial for acute treatment in patients with orthodromic AVRT "(Level of Evidence: B-R) " |
"3. Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with
AVRT if vagal maneuvers or adenosine are ineffective or not feasible "(Level of Evidence: B-NR) " |
"4. Synchronized cardioversion is recommended for acute treatment in hemodynamically stable patients with AVRT
when pharmacological therapy is ineffective or contraindicated "(Level of Evidence: B-NR) " |
"5. Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with
pre-excited AF"(Level of Evidence: B-NR ) " |
"6. Ibutilide or intravenous procainamide is beneficial for acute treatment in patients with pre-excited AF
who are hemodynamically stable "(Level of Evidence: C-LD) " |
Class IIa |
"1. Intravenous diltiazem, verapamil "(Level of Evidence: B-R) or beta blockers can be effective for acute treatment in patients with orthodromic AVRT who do not have preexcitation
on their resting ECG during sinus rhythm "(Level of Evidence: C-LD) " |
Class IIb |
"1. Intravenous beta blockers, diltiazem, or verapamil might be considered for acute treatment in patients with orthodromic
AVRT who have pre-excitation on their resting ECG and have not responded to other therapies"(Level of Evidence:B-R) " |
Class III(harm) |
"1. Intravenous digoxin, intravenous amiodarone, intravenous or oral beta blockers, diltiazem, and verapamil are
potentially harmful for acute treatment in patients with pre-excited AF ( "(Level of Evidence: C-LD) " |
Management of ongoing Orthodromic AVRT
Class I |
"1.Catheter ablation of the accessory pathway is recommended in patients with AVRT and/or pre-excited AF"(Level of Evidence: B-NR) " |
"2.Oral beta blockers, diltiazem, or verapamil are indicated for ongoing management of AVRT in patients without
pre-excitation on their resting ECG "(Level of Evidence: C-LD) " |
Class IIa |
"1.Oral flecainide or propafenone is reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have AVRT and/or pre-excited AF and are not candidates for, or prefer not to undergo, catheter ablation"(Level of Evidence: C-LD) " |
Class IIb |
"1.Oral dofetilide or sotalol may be reasonable for ongoing management in patients with AVRT and/or pre-excited
AF who are not candidates for, or prefer not to undergo, catheter ablation"(Level of Evidence:B-R) " |
"2.Oral amiodarone may be considered for ongoing management in patients with AVRT and/or pre-excited AF who are not candidates for, or prefer not to undergo, catheter ablation and in whom beta blockers, diltiazem, flecainide, propafenone, and verapamil are ineffective or contraindicated"(Level of Evidence:C-LD) " |